Ubs Group Ag Cytokinetics Inc Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Cytokinetics Inc stock. As of the latest transaction made, Ubs Group Ag holds 3,070,665 shares of CYTK stock, worth $105 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,070,665
Previous 2,134,219
43.88%
Holding current value
$105 Million
Previous $85.8 Million
18.28%
% of portfolio
0.02%
Previous 0.02%
Shares
34 transactions
Others Institutions Holding CYTK
# of Institutions
368Shares Held
129MCall Options Held
3.62MPut Options Held
1.12M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$604 Million0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$503 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$411 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$269 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$219 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.23B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...